Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic
phase, to which treatments can contribute. The anticholinergic properties of medications, ie …

Background Patients with psychotic disorders are often treated with numerous medications,
many of which have anticholinergic activity. We assessed cognition in relation to the …

BackgroundCognitive deficits are a well-established feature of bipolar disorders (BD), even
during periods of euthymia, but risk factors associated with cognitive deficits in euthymic BD …

Aims: Previous comparisons of cognitive decline among patients with bipolar disorder (BD)
and schizophrenia (SZ) have found somehow quite similar profiles of deficits, but results …

Objectives: Cognitive impairment may affect patients with Bipolar Disorder (BD) beyond the
acute episodes, qualifying as a potential endophenotype. However, which cognitive …

Objectives Although cognitive dysfunction is a prominent feature of bipolar disorder (BD),
previous research presents limitations in estimating the proportion of euthymic patients …

The last decade has witnessed a growing interest in the neuropsychological study of bipolar
disorder (BD). This chronic mood disorder is associated with persistent neurocognitive …

Objective: Many psychotropic medications used to treat schizophrenia have significant
anticholinergic properties, which are linked to cognitive impairment and dementia risk in …

Available evidence concerning the side effects experienced by bipolar disorder (BD)
patients under naturalistic conditions has been poorly investigated. The aim of this study …

Objectives Neurocognitive deficits have been widely reported in euthymic Bipolar Disorder
(BD) patients and contribute to functional disability. However, the longitudinal trajectory of …